Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07085091). This is a study registration, not published results. Lead sponsor: ALX Oncology Inc.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 170 participants (ESTIMATED). Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC). Interventions: DRUG: ALX2004; DRUG: ALX2004; DRUG: ALX2004. Primary outcome measures: Phase 1a: Incidence of dose limiting toxicities (DLTs) , Up to 28 days; Phase 1a: Incidence of treatment emergent adverse events , Up to 2 years from first dose; Phase 1b: Overall Response Rate (ORR) per investigator assessment using RECIST v1.1 , Up to 2 years from first patient dosed in dose expansion phase. Brief summary: A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors